191 related articles for article (PubMed ID: 18635692)
1. Antimanic potency of typical neuroleptic drugs and affinity for dopamine D2 and serotonin 5-HT2A receptors--a new analysis of data from the archives and implications for improved antimanic treatments.
Harrison-Read PE
J Psychopharmacol; 2009 Nov; 23(8):899-907. PubMed ID: 18635692
[TBL] [Abstract][Full Text] [Related]
2. Atypical antipsychotics: mechanism of action.
Seeman P
Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
[TBL] [Abstract][Full Text] [Related]
3. Serotonin receptors: their key role in drugs to treat schizophrenia.
Meltzer HY; Li Z; Kaneda Y; Ichikawa J
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974
[TBL] [Abstract][Full Text] [Related]
4. [Quetiapin in bipolar disorders].
Sümegi A
Neuropsychopharmacol Hung; 2008 Dec; 10(5):281-91. PubMed ID: 19419014
[TBL] [Abstract][Full Text] [Related]
5. Serotonin 5-HT2 receptor, dopamine D2 receptor, and alpha 1 adrenoceptor antagonists. Conformationally flexible analogues of the atypical antipsychotic sertindole.
Andersen K; Liljefors T; Hyttel J; Perregaard J
J Med Chem; 1996 Sep; 39(19):3723-38. PubMed ID: 8809161
[TBL] [Abstract][Full Text] [Related]
6. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity.
Leysen JE; Janssen PM; Megens AA; Schotte A
J Clin Psychiatry; 1994 May; 55 Suppl():5-12. PubMed ID: 7520908
[TBL] [Abstract][Full Text] [Related]
7. Receptor mechanisms in the treatment of schizophrenia.
Reynolds GP
J Psychopharmacol; 2004 Sep; 18(3):340-5. PubMed ID: 15358977
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacology of second-generation antipsychotics: a validity of the serotonin-dopamine hypothesis].
Kuroki T
Nihon Shinkei Seishin Yakurigaku Zasshi; 2004 Oct; 24(5):257-64. PubMed ID: 15658501
[TBL] [Abstract][Full Text] [Related]
9. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice.
Stahl SM; Shayegan DK
J Clin Psychiatry; 2003; 64 Suppl 19():6-12. PubMed ID: 14728084
[TBL] [Abstract][Full Text] [Related]
10. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and binding affinity of potential atypical antipsychotics with the tetrahydroquinazolinone motif.
Carro L; Raviña E; Domínguez E; Brea J; Loza MI; Masaguer CF
Bioorg Med Chem Lett; 2009 Nov; 19(21):6059-62. PubMed ID: 19796944
[TBL] [Abstract][Full Text] [Related]
12. [Neuroprotective effect of antipsychotic drugs (neuroleptics) in global brain ischemia].
Kulinskiĭ VI; Gavrilov SS
Eksp Klin Farmakol; 2006; 69(4):19-22. PubMed ID: 16995432
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics.
Bardin L; Auclair A; Kleven MS; Prinssen EP; Koek W; Newman-Tancredi A; Depoortère R
Behav Pharmacol; 2007 Mar; 18(2):103-18. PubMed ID: 17351418
[TBL] [Abstract][Full Text] [Related]
14. Novel 4-alkyl-1-arylpiperazines and 1,2,3,4-tetrahydroisoquinolines containing diphenylmethylamino or diphenylmethoxy fragment with differentiated 5-HT1A/5-HT2A/D2 receptor activity.
Paluchowska MH; Mokrosz MJ; Charakchieva-Minol S; Duszyńska B; Kozioł A; Wesołowska A; Stachowicz K; Chojnacka-Wójcik E
Pol J Pharmacol; 2003; 55(4):543-52. PubMed ID: 14581712
[TBL] [Abstract][Full Text] [Related]
15. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens.
Kuroki T; Meltzer HY; Ichikawa J
J Pharmacol Exp Ther; 1999 Feb; 288(2):774-81. PubMed ID: 9918588
[TBL] [Abstract][Full Text] [Related]
16. Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors.
Stockmeier CA; DiCarlo JJ; Zhang Y; Thompson P; Meltzer HY
J Pharmacol Exp Ther; 1993 Sep; 266(3):1374-84. PubMed ID: 8103793
[TBL] [Abstract][Full Text] [Related]
17. Long-term effects of JL 13, a potential atypical antipsychotic, on rat dopamine and serotonin receptor subtypes.
Moran-Gates T; Massari C; Graulich A; Liégeois JF; Tarazi FI
J Neurosci Res; 2006 Aug; 84(3):675-82. PubMed ID: 16810690
[TBL] [Abstract][Full Text] [Related]
18. Comparing sertindole to other new generation antipsychotics on preferential dopamine output in limbic versus striatal projection regions: mechanism of action.
Hertel P
Synapse; 2006 Dec; 60(7):543-52. PubMed ID: 16952163
[TBL] [Abstract][Full Text] [Related]
19. Spiperone: influence of spiro ring substituents on 5-HT2A serotonin receptor binding.
Metwally KA; Dukat M; Egan CT; Smith C; DuPre A; Gauthier CB; Herrick-Davis K; Teitler M; Glennon RA
J Med Chem; 1998 Dec; 41(25):5084-93. PubMed ID: 9836624
[TBL] [Abstract][Full Text] [Related]
20. [35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents.
Newman-Tancredi A; Audinot V; Chaput C; Verrièle L; Millan MJ
J Pharmacol Exp Ther; 1997 Jul; 282(1):181-91. PubMed ID: 9223553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
